Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Needham & Company Awaits NDA Filing, Reit Buy on Sarepta Therapeutics (SRPT)
May 7, 2015 11:22 AM EDTNeedham & Company reiterate their Buy rating on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with the price target set $38 while awaiting the NDA filing and approval of Eteplirsen.
Needham & Company analyst, Chad Messer, commented on SRPT, saying, "A pre-NDA meeting with the FDA... More
